Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1

[1]  Lippincott-Schwartz,et al.  Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .

[2]  M. Doll,et al.  Functional characterization of the A411T (L137F) and G364A (D122N) genetic polymorphisms in human N-acetyltransferase 2 , 2007, Pharmacogenetics and genomics.

[3]  G. Shaw,et al.  Risk of limb deficiency defects associated with NAT1, NAT2, GSTT1, GSTM1, and NOS3 genetic variants, maternal smoking, and vitamin supplement intake , 2006, American journal of medical genetics. Part A.

[4]  X. Jianming,et al.  N-Acetyltransferase-1 gene polymorphisms and correlation between genotype and its activity in a central Chinese Han population. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[5]  M. Doll,et al.  Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1 , 2006, Pharmacogenetics and genomics.

[6]  L. E. Mitchell,et al.  Loss of function polymorphisms in NAT1 protect against spina bifida , 2006, Human Genetics.

[7]  D. Hein,et al.  N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk , 2006, Oncogene.

[8]  Andrew D. Johnson,et al.  Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability , 2005, Pharmacogenetics and genomics.

[9]  L. E. Mitchell,et al.  The NAT1 C1095A polymorphism, maternal multivitamin use and smoking, and the risk of spina bifida. , 2005, Birth defects research. Clinical and molecular teratology.

[10]  G. Fakis,et al.  Arylamine N-Acetyltransferases: What We Learn from Genes and Genomes , 2005, Drug metabolism reviews.

[11]  G. Shaw,et al.  Periconceptional multivitamin intake during early pregnancy, genetic variation of acetyl-N-transferase 1 (NAT1), and risk for orofacial clefts. , 2004, Birth defects research. Part A, Clinical and molecular teratology.

[12]  J. States,et al.  The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. , 2004, Pharmacogenetics.

[13]  J. States,et al.  Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). , 2004, Pharmacogenetics.

[14]  R. Minchin,et al.  Proteasomal Degradation of N-Acetyltransferase 1 Is Prevented by Acetylation of the Active Site Cysteine , 2004, Journal of Biological Chemistry.

[15]  G. Shaw,et al.  Maternal Smoking and the Risk of Orofacial Clefts: Susceptibility With NAT1 and NAT2 Polymorphisms , 2004, Epidemiology.

[16]  D. Hein.  Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. , 2002, Mutation research.

[17]  M. Doll,et al.  Rapid genotype method to distinguish frequent and/or functional polymorphisms in human N-acetyltransferase-1. , 2002, Analytical biochemistry.

[18]  M. Doll,et al.  Functional Genomics of C190T Single Nucleotide Polymorphism in Human N-Acetyltransferase 2 , 2002, Biological chemistry.

[19]  R. Minchin,et al.  Pharmacogenetics of the arylamine N-acetyltransferases , 2002, The Pharmacogenomics Journal.

[20]  M. Doll,et al.  Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1. , 2001, Pharmacogenetics.

[21]  W. Weber,et al.  Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1. , 2000, Molecular pharmacology.

[22]  D. Grant,et al.  Update on consensus arylamine N-acetyltransferase gene nomenclature. , 2000, Pharmacogenetics.

[23]  H. Dhaini,et al.  Arylamine N-acetyltransferase 1 (NAT1) genotypes in a Lebanese population. , 2000, Pharmacogenetics.

[24]  M. Doll,et al.  Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[25]  M. Doll,et al.  Molecular Genetics and Epidemiology of the NAT 1 and NAT 2 Acetylation Polymorphisms 1 , 2000 .

[26]  J. Brockmöller,et al.  Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). , 1999, Biochemical pharmacology.

[27]  J. Basilion,et al.  Single-nucleotide polymorphisms can cause different structural folds of mRNA. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Rustan,et al.  Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse. , 1999, The Journal of pharmacology and experimental therapeutics.

[29]  N. Probst-Hensch,et al.  Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. , 1998, Pharmacogenetics.

[30]  D. Grant,et al.  Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. , 1998, Pharmacogenetics.

[31]  R. Minchin,et al.  Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560A mutations. , 1998, Pharmacogenetics.

[32]  D. Grant,et al.  Human acetyltransferase polymorphisms. , 1997, Mutation research.

[33]  T. Rustan,et al.  Identification of a novel allele at the human NAT1 acetyltransferase locus. , 1997, Biochemical and biophysical research communications.

[34]  D. Grant,et al.  Study of the role of the highly conserved residues Arg9 and Arg64 in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis. , 1997, The Biochemical journal.